Showing results (241-250 of 1,869) with videos related to
Sort By:
Pageof 187
Current Cancer Drug Targets|April 8, 2010
Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancerNuzhat Ahmed, Khalid Abubaker, Jock Findlay, et al.Current Cancer Drug Targets|June 11, 2009
Targeting the mevalonate pathway for improved anticancer therapyG FritzCurrent Cancer Drug Targets|June 11, 2009
Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathwaysM Caraglia, M Marra, P Tagliaferri, et al.Current Cancer Drug Targets|April 14, 2010
The mTOR pathway: a new target in cancer therapyL Ciuffreda, C Di Sanza, U C Incani, et al.Current Cancer Drug Targets|April 14, 2010
Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cellsSilvia Carloni, Francesco Fabbri, Giovanni Brigliadori, et al.Current Cancer Drug Targets|May 17, 2007
MUC1 is a promising therapeutic target for prostate cancer therapyY Li, P J CozziCurrent Cancer Drug Targets|March 10, 2007
From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus developmentAnne Moon Crompton, David H KirnCurrent Cancer Drug Targets|March 10, 2007
Clinical trials with oncolytic adenovirus in ChinaWang Yu, Hu FangCurrent Cancer Drug Targets|March 10, 2007
Regulatory aspects of oncolytic virus productsTeruhide Yamaguchi, Eriko UchidaCurrent Cancer Drug Targets|December 16, 2006
Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapyE Ritchie, G NicholsPageof 187